213 related articles for article (PubMed ID: 37400463)
1. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
Wang L; Peng JL
Sci Rep; 2023 Jul; 13(1):10755. PubMed ID: 37400463
[TBL] [Abstract][Full Text] [Related]
2. The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression.
Wang Q; Huang Y; Zhu Y; Zhang W; Wang B; Du X; Dai Q; Zhang F; Fang Z
Cancer Med; 2024 Apr; 13(7):e7165. PubMed ID: 38613157
[TBL] [Abstract][Full Text] [Related]
3. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
Yin Z; Ma T; Chen S; Yu M
Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
[TBL] [Abstract][Full Text] [Related]
4. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
6. The novel m6A writer METTL5 as prognostic biomarker probably associating with the regulation of immune microenvironment in kidney cancer.
Wei Zhang ; Chen Y; Zeng Z; Peng Y; Li L; Hu N; Gao X; Cai W; Yin L; Xu Y; Zhang X; Tang D; Dai Y
Heliyon; 2022 Dec; 8(12):e12078. PubMed ID: 36619469
[TBL] [Abstract][Full Text] [Related]
7. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
[TBL] [Abstract][Full Text] [Related]
8. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
[TBL] [Abstract][Full Text] [Related]
9. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
Wang X; Yang J; Luo L; Li X; Zhang Y
Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
[TBL] [Abstract][Full Text] [Related]
10. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
12. Prognostic potential of PRPF3 in hepatocellular carcinoma.
Liu Y; Yang Y; Luo Y; Wang J; Lu X; Yang Z; Yang J
Aging (Albany NY); 2020 Jan; 12(1):912-930. PubMed ID: 31926109
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Prognostic Value, Immune Implication and Biological Function of
Huang Y; Huang S; Ma L; Wang Y; Wang X; Xiao L; Qin W; Li L; Yuan X
Front Immunol; 2021; 12():723293. PubMed ID: 34899687
[TBL] [Abstract][Full Text] [Related]
14. H2AFX might be a prognostic biomarker for hepatocellular carcinoma.
Hu H; Zhong T; Jiang S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1684. PubMed ID: 35903980
[TBL] [Abstract][Full Text] [Related]
15. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
[TBL] [Abstract][Full Text] [Related]
16. MJDs family members: Potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.
Zhou L; Chen G; Liu T; Liu X; Yang C; Jiang J
Front Genet; 2022; 13():965805. PubMed ID: 36159990
[TBL] [Abstract][Full Text] [Related]
17. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.
Gu Y; Li X; Bi Y; Zheng Y; Wang J; Li X; Huang Z; Chen L; Huang Y; Huang Y
Aging (Albany NY); 2020 Jan; 12(1):784-807. PubMed ID: 31927532
[TBL] [Abstract][Full Text] [Related]
18. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.
Shen W; Yuan L; Cheng F; Wu Z; Li X
Genes Genomics; 2024 Jan; 46(1):49-64. PubMed ID: 37985547
[TBL] [Abstract][Full Text] [Related]
19. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Wu Y; Xu X
Life Sci; 2021 Jan; 265():118799. PubMed ID: 33220285
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic potential of ribosome 18S RNA m
Wang Z; Liu J; Yang Y; Xing C; Jing J; Yuan Y
Cancer Cell Int; 2021 Oct; 21(1):569. PubMed ID: 34702266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
